Abstracts tagged "biologic drugs and uveitis"

Abstract Number: 1159 • 2017 ACR/ARHP Annual Meeting
National Recommendations on the Use of Immunomodulatory Drugs in Patients with NON-Infectious NON-Malignant Anterior Uveitis
Gerard Espinosa¹, Santiago Muñoz², Jose M Ruiz de Morales³, Jose M Herreras⁴ and Miguel Cordero-Coma⁵, ¹Autoimmune Diseases Department. Hospital Clínic de Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Infanta Sofia, Madrid, Spain, ³Complejo Asistencial Universitario de León, León, Spain, ⁴Ophthalmology, Hospital Universitario, IOBA, Valladolid, Spain, ⁵Ophthalmology, Hospital de León. Spain, León, Spain
Background/Purpose: Anterior uveitis (AU) is the most common pattern of uveitis, that migh lead to important ocular complications including blindness. Immunomodulatory drugs have been used…
Abstract Number: 2098 • 2017 ACR/ARHP Annual Meeting
Systemic Treatment for ACUTE Anterior Uveitis ( SYNTHETIC AND BIOLOGIC DISEASE-MODIFYINGANTIRHEUMATIC DRUGS) : A Systematic Literature Review
Alejandro Gómez-Gómez¹, Estibaliz Loza², Maria P Rosario³, Gerard Espinosa⁴, Jose M Ruiz de Morales⁵, Jose M Herreras⁶, Santiago Muñoz⁷ and Miguel Cordero-Coma⁸, ¹Hospital Universitario Infanta Sofía, Madrid, Spain, ²Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, ³Instituto de Salud Musculoesquelética, Madrid, Spain, ⁴Autoimmune Diseases Department. Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Complejo Asistencial Universitario de León, León, Spain, ⁶Ophthalmology, Hospital Universitario, IOBA, Valladolid, Spain, ⁷Rheumatology, Hospital Infanta Sofia, Madrid, Spain, ⁸Ophthalmology, Hospital de León. Spain, León, Spain
Background/Purpose: Acute anterior uveitis (AAU) is the most common form of uveitis. One third of AAU patients may present recurrences, some requiring systemic disease-modifying antirheumatic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].